A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
E
Eades SK, Boineau FG, Christensen ML. Increased tacrolimus levels in a pediatric renal transplant patient attributed to chronic diarrhea. Pediatr Transplant 2000; 4:63-6.
Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44:190-4.
Eagling VA, Howe JL, Barry MJ, Back DJ. The metabolism of zidovudine by human liver microsomes in vitro: formation of 3’-amino-3’-deoxythymidine. Biochem Pharmacol 1994; 48:267-76.
Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 1999; 48:543-52.
Eagling VA, Tjia JF, Back DJ. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 1998; 45:107-14.
Eagling VA, Wiltshire H, Whitcombe IW, Back DJ. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 2002; 32:1-17.
Eap CB, Bender S, Gastpar M et al. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. Ther Drug Monit 2000; 22:209-14.
Eap CB, Bertel-Laubscher R, Zullino D, Amey M, Baumann P. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. Pharmacopsychiatry 2000; 33:112-5.
Eap CB, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 1997; 17:113-7.
Eap CB, Bochud M, Elston RC et al. CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. Hypertension 2007; 49:1007-14.
Eap CB, Bondolfi G, Zullino D et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 2001; 21:330-4.
Eap CB, Bondolfi G, Zullino D et al. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Ther Drug Monit 2001; 23:228-31.
Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41:1153-93.
Eap CB, Buclin T, Hustert E et al. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 2004; 60:231-6.
Eap CB, Fellay J, Buclin T et al. CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. Pharmacogenetics 2004; 14:255-60.
Eap CB, Guentert TW, Schãublin-Loidl M et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996; 59:322-31.
Eap CB, Lima CA, Macciardi F, Woggon B, Powell K, Baumann P. Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. Ther Drug Monit 1998; 20:7-13.
Eap CB, Yasui N, Kaneko S et al. Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. Ther Drug Monit 1999; 21:166-70.
Eason DD, Shepherd AT, Blanck G. Interferon regulatory factor 1 tryptophan 11 to arginine point mutation abolishes DNA binding. Biochim Biophys Acta 1999; 1446:140-4.
Easterbrook J, Fackett D, Li AP. A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4’-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6beta-hydroxylation. Chem Biol Interact 2001; 134:243-9.
Easterbrook J, Lu C, Sakai Y, Li AP. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 2001; 29:141-4.
Easton DF, Bishop DT, Ford D, Crockford GP. Breast Cancer Linkage Consortium: Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993; 52:678-701.
Easton DF, Deffenbaugh AM, Pruss D et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007; 81:873-83.
Easton N, Fry J, O’Shea E, Watkins A, Kingston S, Marsden CA. Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). Brain Res 2003; 987:144-54.
Eaton DL. Biotransformation enzyme polymorphism and pesticide susceptibility. Neurotoxicology 2000; 21:101-11.
Ebbin AJ, Huntley C, Tranquada RE. Symptomatic leucine sensitivity in a mother and daughter. Metabolism 1967; 16:926-32.
Ebdrup S, Refsgaard HH, Fledelius C, Jacobsen P. Synthesis and structure-activity relationship for a novel class of potent and selective carbamate-based inhibitors of hormone selective lipase with acute in vivo antilipolytic effects. J Med Chem 2007; 50:5449-56.
Ebert B, Kisiela M, Malátková P, El-Hawari Y, Maser E. Regulation of human carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells. Biochemistry 2010; 49:8499-511.
Ebert B, Kisiela M, Wsól V, Maser E. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29. Chem Biol Interact 2011; 191:239-49.
Eberwein P, Hiss S, Auw-Haedrich C et al. Epithelial marker expression in Salzmann nodular degeneration shows characteristics of limbal transient amplifying cells and alludes to an involvement of the epithelium in its pathogenesis. Acta Ophthalmol 2010; 88:184-9.
Ebina M, Shibazaki M, Kudo K, Kasai S, Kikuchi H. Correlation of dysfunction of nonmuscle myosin IIA with increased induction of Cyp1a1 in Hepa-1 cells. Biochim Biophys Acta 2011; 1809:176-83.
Ebisawa A, Hiratsuka M, Sakuyama K, Konno Y, Sasaki T, Mizugaki M. Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6 gene in Japanese individuals. Drug Metab Pharmacokinet 2005; 20:294-9.
Ebisawa T, Kajimura N, Uchiyama M et al. Alleic variants of human melatonin 1a receptor: function and prevalence in subjects with circadian rhythm sleep disorders. Biochem Biophys Res Commun 1999; 262:832-7.
Ebmeier CC, Anderson RJ. Human thyroid phenol sulfotransferase enzymes 1A1 and 1A3: activities in normal and diseased thyroid glands, and inhibition by thyroid hormones and phytoestrogens. J Clin Endocrinol Metab 2004; 89:5597-605.
Ebrahim S, Lawlor DA, Shlomo YB et al. Alcohol dehydrogenase type 1C (ADH1C) variants, alcohol consumption traits, HDL-cholesterol and risk of coronary heart disease in women and men: British Women’s Heart and Health Study and Caerphilly cohorts. Atherosclerosis 2008; 196:871-8.
Ebrahimi A, Houshmand M, Tonekaboni SH, Fallah Mahboob Passand MS, Zainali S, Moghadasi M. Two novel mutations in SCN1A gene in Iranian patients with epilepsy. Arch Med Res 2010; 41:207-14.
Ebrahimi M, Mohammadi P, Daryadel A, Baharvand H. Assessment of heat shock protein (HSP60, HSP72, HSP90, and HSC70) expression in cultured limbal stem cells following air lifting. Mol Vis 2010; 16:1680-8.
Ebstein RP, Novick O, Umansky R et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet1996; 12:78-80.
Eck P, Erichsen HC, Taylor JG et al. Comparison of the genomic structure and variation in the two human sodium-dependent vitamin C transporters, SLC23A1 and SLC23A2. Hum Genet 2004; 4:285-94.
Ecker J, Liebisch G, Patsch W, Schmitz G. The conjugated linoleic acid isomer trans-9,trans-11 is a dietary occurring agonist of liver X receptor alpha. Biochem Biophys Res Commun 2009; 388:660-6.
Eckermann G, Lahu G, Nassr N, Bethke TD. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults. J Clin Pharmacol 2011. doi:10. 1177/0091270010389467.
Eckey R, Agarwal DP, Saha N, Goedde HW. Detection and partial characterization of a variant form of cytosolic aldehyde dehydrogenase isozyme. Hum Genet 1986; 72:95-7.
Eckhardt LL, Farley AL, Rodriguez E et al. KCNJ2 mutations in arrhythmia patients referred for LQT testing: a mutation T305A with novel effect on rectification properties. Heart Rhythm 2007; 4:323-9.
Eckman CB, Metha ND, Crook R et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A-beta-42(43). Hum Mol Genet 1997; 6:2087-9.
Echizen H, Tanizaki M, Tatsuno J et al. Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. Drug Metab Dispos 2000; 28:937-44.
Eddahibi S, Adnot S. Serotonin and pulmonary arterial hypertension. Rev Mal Respir 2006; 23:45-51.
Edenberg HJ. Regulation of the mammalian alcohol dehydrogenase genes. Prog Nucleic Acids Res Molec Biol 2000; 64:295-341.
Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res Health 2007; 30:5-13.
Edenberg HJ, Xuei X, Chen HJ et al. Association of alcohol dehydrogenase genes with alcohol dependence: a comprehensive analysis. Hum Mol Genet 2006; 15:1539-49.
Eder C, Frankenberger M, Stanzel F et al. Ultrafine carbon particles down-regulate CYP1B1 expression in human monocytes. Part Fibre Toxicol 2009; 6:27.
Edin ML, Wang Z, Bradbury JA et al. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J 2011; 25:3436-47.
Edison E, Shaji RV, Srivastava A, Chandy M. Hyperbilirubinemia in homozygous HbE disease is associated with the UGT1A1 gene polymorphism. Hemoglobin 2005; 29:189-95.
Edmondson AC, Braund PS, Stylianou IM et al. Dense genotyping of candidate gene loci identifies variants associated with high-density lipoprotein cholesterol. Circ Cardiovasc Genet 2011; 4:145-55.
Edsbäcker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn’s disease. Clin Pharmacokinet 2004; 43:803-21.
Edvardsen H, Brunsvig PF, Solvang H et al. SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. Pharmacogenomics J 2010; 10:513-23.
Edwards DJ, Fitzsimmons ME, Schuetz EG et al. 6’,7’-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999; 65:237-44.
Edwards FL, Tchounwou PB. Environmental toxicology and health effects associated with methyl parathion exposure-a scientific review. Int J Environ Res Public Health 2005; 2:430-41.
Edwards RJ, Adams DA, Watts PS, Davies DS, Boobis AR. Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 1998; 56:377-87.
Edwards RJ, Price RJ, Watts PS et al. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2003; 31:282-8.
Edwards RJ, Singleton AM, Murray BP, Davies DS, Boobis AR. Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes. Biochem Pharmacol 1995; 49:39-47.
Edwards TL, Gilbert JR, Haines JL, Martin ER, Pericak-Vance M, Ritchie MD. An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3. Am J Med Genet B Neuropsychiatr Genet 2009; 150:721-35.
Edwards TL, Pericak-Vance M, Gilbert JR, Haines JL, Martin ER, Ritchie MD. An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3. Am J Med Genet B Neuropsychiatr Genet 2009; 150:721-35.
Eechoute K, Sparreboom A, Burger H et al. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 2011; 17:406-15.
Efendiev R, Krmar RT, Ogimoto G et al. Hypertension-linked mutation in the adducin alpha-subunit leads to higher AP2-mu-2 phosphorylation and impaired Na+, K+-ATPase trafficking in response to GPCR signals and intracellular sodium. Circ Res 2004; 95:1100-8.
Effendi K, Mori T, Komuta M, Masugi Y, Du W, Sakamoto M. Bmi-1 gene is upregulated in early-stage hepatocellular carcinoma and correlates with ATP-binding cassette transporter B1 expression. Cancer Sci 2010; 101:666-72.
Efrati E, Elkin H, Sprecher E, Krivoy N. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population. Curr Drug Saf 2010; 5:190-3.
Egan MF, Straub RE, Goldberg TE et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 2004; 101:12604-9.
Egashira K, Ohtani H, Itoh S et al. Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab Dispos 2004; 32:828-33.
Egecioglu E, Bjursell M, Ljungberg A et al. Growth hormone receptor deficiency results in blunted ghrelin feeding response, obesity, and hypolipidemia in mice. Am J Physiol Endocrinol Metab 2006; 290:317-25.
Egensperger R, Bancher C, Kosel S et al. The apolipoprotein E epsilon-4 allele in Parkinson’s disease with Alzheimer’s lesions. Biochem Biophys Res Commun 1996; 224:484-6.
Egnell AC, Houston B, Boyer S. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 2003; 305:1251-62.
Egnell AC, Houston JB, Boyer CS. Predictive models of CYP3A4 Heteroactivation: in vitro-in vivo scaling and pharmacophore modeling. J Pharmacol Exp Ther 2005; 312:926-37.
Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998; 58:2385-96.
Ehata S, Johansson E, Katayama R et al. Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. Oncogene 2011; 30:1693-705.
Ehlers CL. Variations in ADH and ALDH in Southwest California Indians. Alcohol Res Health 2007; 30:14-7.
Ehmer U, Vogel A, Schütte JK, Krone B, Manns MP, Strassburg CP. Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 2004; 39:970-7.
Ehnert S, Nussler AK, Lehmann A, Dooley S. Blood monocyte-derived neohepatocytes as in vitro test system for drug metabolism. Drug Metab Dispos 2008; 36:1922-9.
Ehnert S, Seeliger C, Vester H et al. Autologous serum improves yield and metabolic capacity of monocyte-derived hepatocyte-like cells: possible implication for cell transplantation. Cell Transplant 2011. doi:10. 3727/096368910X550224.
Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Drug Saf 2007; 6:289-303.
Ehringer MA, Clegg HV, Collins AC et al. Association of the neuronal nicotinic receptor beta2 subunit gene (CHRNB2) with subjective responses to alcohol and nicotine. Am J Med Genet B Neuropsychiatr Genet 2007; 144:596-604.
Eichelbaum M, Baur MP, Dengler HJ et al. Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 1987; 23:455-8.
Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57:119-37.
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16:183-7.
Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S. Development of a drug resistance model for hepatoblastoma. Int J Oncol 2011; 38:447-54.
Eidelman O, Zhang J, Srivastava M, Pollard HB. Cystic fibrosis and the use of pharmacogenomics to determine surrogate endpoints for drug discovery. Am J Pharmacogenomics 2001; 1:223-38.
Eiden C, Cociglio M, Hillaire-Buys D et al. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring. Xenobiotica 2010; 40:701-6.
Eiden C, Palenzuela G, Hillaire-Buys D et al. Posaconazole-increased vincristine neurotoxicity in a child: a case report. J Pediatr Hematol Oncol 2009; 31:292-5.
Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44:439-46.
Eijgelsheim M, Visser LE, Uitterlinden AG, Stricker BH. Protective effect of a GRK5 polymorphism on heart failure and its interaction with beta-adrenergic receptor antagonists. Pharmacogenomics 2008; 9:1551-5.
Eilertsen KE, Mæhre HK, Cludts K, Olsen JO, Hoylaerts MF. Dietary enrichment of apolipoprotein E-deficient mice with extra virgin olive oil in combination with seal oil inhibits atherogenesis. Lipids Health Dis 2011; 10:41.
Einarsdóttir K, Darabi H, Li Y et al. ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res 2008; 10:15.
Einbond LS, Soffritti M, Esposti DD et al. Actein activates stress- and statin-associated responses and is bioavailable in Sprague-Dawley rats. Fundam Clin Pharmacol 2009; 23:311-21.
Einem Lindeman T, Poirier MC, Divi RL. The resveratrol analogue, 2,3’,4,5’-tetramethoxystilbene, does not inhibit CYP gene expression, enzyme activity and benzo[a]pyrene-DNA adduct formation in MCF-7 cells exposed to benzo[a]pyrene. Mutagenesis 2011; 26:629-35.
Einstein MH, Leanza S, Chiu LG et al. Genetic variants in TAP are associated with high-grade cervical neoplasia. Clin Cancer Res 2009; 15:1019-23.
Eis PS, Garcia-Blanco MA. Quantification of microRNAs, splicing isoforms, and homologous mRNAs with the invader assay. Methods Mol Biol 2008; 488:279-318.
Eisele S, Garbe E, Zeitz M, Schneider T, Somasundaram R. Ciprofloxacin-related acute severe myalgia necessitating emergency care treatment: a case report and review of the literature. Int J Clin Pharmacol Ther 2009; 47:165-8.
Eiselt R, Domanski TL, Zibat A et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001; 11:447-58.
Eisenach JH, McGuire AM, Schwingler RM, Turner ST, Joyner MJ. The Arg16/Gly beta2-adrenergic receptor polymorphism is associated with altered cardiovascular responses to isometric exercise. Physiol Genomics 2004; 16:323-8.
Eisenhardt A, Sperling H, Hauck E et al. ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction. Urology 2003; 62:152-7.
Eisenmann KM, Dykema KJ, Matheson SF et al. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene 2009; 28:3429-41.
Ejsing TB, Pedersen AD, Linnet K. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum Psychopharmacol 2005; 20:493-500.
Ek CJ, Wong A, Liddelow SA, Johansson PA, Dziegielewska KM, Saunders NR. Efflux mechanisms at the developing brain barriers: ABC-transporters in the fetal and postnatal rat. Toxicol Lett 2010; 197:51-9.
Ek M, Söderdahl T, Küppers-Munther B et al. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol 2007; 74:496-503.
Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008; 18:515-23.
Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol 2009; 67:50-60.
Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics 2008; 18:1009-15.
Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev 2009; 35:18-31.
Ekins S, Berbaum J, Harrison RK. Generation and validation of rapid computational filters for cyp2d6 and cyp3a4. Drug Metab Dispos 2003; 31:1077-80.
Ekins S, Bravi G, Binkley S et al. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. J Pharmacol Exp Ther 1999; 290:429-38.
Ekins S, Bravi G, Wikel JH, Wrighton SA. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther 1999; 291:424-33.
Ekins S, Bugrim A, Brovold L et al. Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms. Xenobiotica 2006; 36:877-901.
Ekins S, Stresser DM, Williams JA. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci 2003; 24:161-6.
Ekroos M, Sjögren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 2006; 103:13682-7.
Ekström G, Gunnarsson UB. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Drug Metab Dispos 1996; 24:955-61.
El BK, Hashimoto Y, Muzandu K et al. Protective effect of Pleurotus cornucopiae mushroom extract on carbon tetrachloride-induced hepatotoxicity. Jpn J Vet Res 2009; 57:109-18.
El Desoky ES, Mohamed HO, Farghaly WM, Hamed SA, Hedaya MA, Siest JP. Study of urinary 6 beta-hydroxycortisol/cortisol ratio in spot urine sample as a biomarker of 3A4 enzyme activity in healthy and epileptic subjects of Egyptian population. Pharmacol Res 2005; 51:575-80.
El Ela AA, Härtter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 2004; 56:967-75.
El Gendy MA, El-Kadi AO. Peganum harmala L. differentially modulates cytochrome P450 gene expression in human hepatoma HepG2 cells. Drug Metab Lett 2009; 3:212-6.
El Hallani S, Ducray F, Idbaih A et al. TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology 2009; 72:332-6.
El Moghrabi S, Houillier P, Picard N et al. Tissue kallikrein permits early renal adaptation to potassium load. Proc Natl Acad Sci USA 2010; 107:13526-31.
El Mouelhi M, Worley DJ, Kuzmak B, Destefano AJ, Thompson GA. Influence of azimilide on CYP2C19-mediated metabolism. J Clin Pharmacol 2004; 44:373-8.
El Mouelhi M, Worley DJ, Kuzmak B, Destefano AJ, Thompson GA. Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2004; 58:641-7.
Elahi A, Bendaly J, Zheng Z et al. Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 2003; 98:872-80.
Elahian F, Kalalinia F, Behravan J. Dexamethasone downregulates BCRP mRNA and protein expression in breast cancer cell lines. Oncol Res 2009; 18:9-15.
Elahian F, Kalalinia F, Behravan J. Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol 2010; 33:113-9.
ElAli A, Hermann DM. Apolipoprotein E controls ATP-binding cassette transporters in the ischemic brain. Sci Signal 2010; 3:ra72.
el-Ashmawy IM, el-Nahas AF, Bayad AE. Teratogenic and cytogenetic effects of ivermectin and its interaction with P-glycoprotein inhibitor. Res Vet Sci 2011; 90:116-23.
Elazar M, Liu M, McKenna SA et al. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology 2009; 137:1827-35.
Elbarbry F, Ragheb A, Attia A, Chibbar R, Marfleet T, Shoker A. Cyclosporine-induced changes in drug metabolizing enzymes in hyperlipemic rabbit kidneys could explain its toxicity. Xenobiotica 2010; 40:772-81.
El-Batch M, Hassan AM, Mahmoud HA. Taurine is more effective than melatonin on cytochrome P450 2E1 and some oxidative stress markers in streptozotocin-induced diabetic rats. J Agric Food Chem 2011; 59:4995-5000.
Elbaz A, Levecque C, Clavel J et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson’s disease. Ann Neurol 2004; 55:430-4.
Elder JT. PSORS1: linking genetics and immunology. J Invest Dermatol 2006; 126:1205-6.
Eldesoky ES, Kamel SI, Farghaly AM, Bakheet MY, Hedaya MA, Siest JP. Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases. Biomark Insights 2007; 1:157-64.
Elefteriou F, Ahn JD, Takeda S et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005; 434:514-20.
Eleftheriou G, Bacis G, Fiocchi R, Sebastiano R. Colchicine-induced toxicity in a heart transplant patient with chronic renal failure. Clin Toxicol 2008; 46:827-30.
Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 2010; 11:1223-34.
Elens L, Yombi JC, Lison D, Wallemacq P, Vandercam B, Haufroid V. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics 2009; 10:1589-97.
Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag 2005; 1:299-306.
El-Gayar S, Ganesh A, Chavarria-Soley G et al. Molecular analysis of CYP1B1 in Omani patients with primary congenital glaucoma: a pilot study. Mol Vis 2009; 15:1325-31.
Elia J, Capasso M, Zaheer Z et al. Candidate gene analysis in an on-going genome-wide association study of attention-deficit hyperactivity disorder: suggestive association signals in ADRA1A. Psychiatr Genet 2009; 19:134-41.
Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, Verhey FR, Visser PJ. Predictive value of APOE-{varepsilon}4 allele for progression from MCI to AD-type dementia: a meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82:1149-56.
Elipe MV, Huskey SE, Zhu B. Application of LC-NMR for the study of the volatile metabolite of MK-0869, a substance P receptor antagonist. J Pharm Biomed Anal 2003; 30:1431-40.
Elisei R, Romei C, Cosci B et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocr Metab 2007; 92:4725-9.
Elizondo G, Medina-Díaz IM. Induction of CYP3A4 by 1alpha,25-dyhydroxyvitamin D3 in HepG2 cells. Life Sci 2003; 73:141-9.
Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005; 44:661-80.
Elkahwaji J, Robin MA, Berson A et al. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol 1999; 57:951-4.
Elkalioubie A, Allorge D, Robriquet L et al. Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer. Eur J Clin Pharmacol 2011; 67:855-8.
Elkayam T, Amitay-Shaprut S, Dvir-Ginzberg M, Harel T, Cohen S. Enhancing the drug metabolism activities of C3A-a human hepatocyte cell line-by tissue engineering within alginate scaffolds. Tissue Eng 2006; 12:1357-68.
El-Khamisy SF, Katyal S, Patel P, Ju L, McKinnon PJ, Caldecott KW. Synergistic decrease of DNA single-strand break repair rates in mouse neural cells lacking both Tdp1 and aprataxin. DNA Repair 2009; 8:760-6.
Elkins JS, Douglas VC, Johnston SC. Alzheimer disease risk and genetic variation in ACE: a meta-analysis. Neurology 2004; 62:363-8.
El-Lakkany NM, Seif el-Din SH, Badawy AA, Ebeid FA. Effect of artemether alone and in combination with grapefruit juice on hepatic drug-metabolising enzymes and biochemical aspects in experimental Schistosoma mansoni. Int J Parasitol 2004; 34:1405-12.
Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 2011; 17:89-99.
El-Omar EM, Carrington M, Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398-402.
El-Rayes BF, Gadgeel S, Parchment R, Lorusso P, Philip PA. A phase I study of flavopiridol and docetaxel. Invest New Drugs 2006; 24:305-10.
El-Rayes BF, Gadgeel S, Shields AF, Manza S, Lorusso P, Philip PA. Phase I study of bryostatin 1 and gemcitabine. Clin Cancer Res 2006; 12:7059-62.
El-Remessy AB, Rajesh M, Mukhopadhyay P et al. Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line. Diabetologia 2011; 54:1567-78.
El-Sankary W, Bombail V, Gibson GG, Plant N. Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos 2002; 30:1029-34.
El-Sankary W, Gibson GG, Ayrton A, Plant N. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 2001; 29:1499-504.
El-Sankary W, Plant NJ, Gibson GG, Moore DJ. Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos 2000; 28:493-6.
El-Sayed WM. Effect of pregnane X receptor (PXR) prototype agonists on chemoprotective and drug metabolizing enzymes in mice. Eur J Pharmacol 2011; 660:291-7.
Elsby R, Gillen M, Butters C et al. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. Drug Metab Dispos 2011; 39:275-82.
El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 2007; 320:229-35.
El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol 2008; 155:1066-75.
El-Sheikh AA, van den Heuvel JJ, Krieger E, Russel FG, Koenderink JB. Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4). Mol Pharmacol 2008; 74:964-71.
El-Shennawy GA, Elbialy AA, Isamil AE, El Behery MM. Is genetic polymorphism of ER-α, CYP1A1, and CYP1B1 a risk factor for uterine leiomyoma? Arch Gynecol Obstet 2011; 283:1313-8.
Elsherbiny ME, El-Kadi AO, Brocks DR. The effect of beta-naphthoflavone on the metabolism of amiodarone by hepatic and extra-hepatic microsomes. Toxicol Lett 2010; 195:147-54.
Elvang AB, Volbracht C, Pedersen LØ et al. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J Neurochem 2009; 110:1377-87.
Ellard S, Bellanné-Chantelot C, Hattersley AT; European Molecular Genetics Quality Network (EMQN) MODY group. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008; 51:546-53.
Ellard S, Colclough K. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum Mutat 2006; 27:854-69.
Elleuch N, Depienne C, Benomar A et al. Mutation analysis of the paraplegin gene (SPG7) in patients with hereditary spastic paraplegia. Neurology 2006; 66:654-9.
Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol 2009; 75:1392-9.
Ellingrod VL, Bishop JR, Moline J, Lin YC, Miller del D. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol Bull 2007; 40:57-62.
Ellingrod VL, Miller D, Schultz SK, Wehring H, Arndt S. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet 2002; 12:55-8.
Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. Am J Health Syst Pharm 1995; 52:2799-812.
Ellingrod VL, Schultz SK, Arndt S. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr Genet 2000; 10:9-11.
Ellinor PT, Nam EG, Shea MA, Milan DJ, Ruskin JN, MacRae CA. Cardiac sodium channel mutation in atrial fibrillation. Heart Rhythm 2008; 1:99-105.
Elliot DJ, Suharjono, Lewis BC et al. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol 2007; 64:450-7.
Elliott DA, Weickert CS, Garner B. Apolipoproteins in the brain: implications for neurological and psychiatric disorders. Clin Lipidol 2010; 51:555-73.
Elliott SL, Crawford C, Mulligan E et al. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia. Br J Haematol 2011; 152:61-71.
Ellis CE, Frielle T. Characterization of two human beta-1-adrenergic receptor transcripts: cloning and alterations in the failing heart. Biochem Biophys Res Commun 1999; 258:552-8.
Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 2001; 116:452-5.
Ellsworth DL, Coady SA, Chen W et al. Influence of the beta2-adrenergic receptor Arg16Gly polymorphism on longitudinal changes in obesity from childhood through young adulthood in a biracial cohort: the Bogalusa Heart Study. Int J Obes Relat Metab Disord 2002; 26:928-37.
Ellsworth DL, Coady SA, Chen W, Srinivasan SR, Boerwinkle E, Berenson GS. Interactive effects between polymorphisms in the beta-adrenergic receptors and longitudinal changes in obesity. Obes Res 2005; 13:519-26.
Ema M, Matsushita N, Sogawa K et al. Human arylhydrocarbon receptor: functional expression and chromosomal assignment to 7p21. J Biochem 1994; 116:845-51.
Emi M, Keicho N, Tokunaga K et al. Association of diffuse panbronchiolitis with microsatellite polymorphism of the human interleukin 8 (IL-8) gene. J Hum Genet 1999; 44:169-72.
Emi Y, Nomura S, Yokota H, Sakaguchi M. ATP-binding cassette transporter isoform C2 localizes to the apical plasma membrane via interactions with scaffolding protein. J Biochem 2011; 149:177-89.
Emile JF, Lamhamedi S, Le Deist F et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998; 80:1432-5.
Emile JF, Théou N, Tabone S et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004; 2:597-605.
Emmelkamp JM, Rockstroh JK. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions-review of the literature. Eur J Med Res 2007; 12:409-17.
Emmenegger U, Shaked Y, Man S et al. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Mol Cancer Ther 2007; 6:2280-9.
Emmerich J, Rosendaal FR, Cattaneo M. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86:809-16.
Emmink BL, van Houdt WJ, Vries RG et al. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology 2011; 141:269-78.
Emoto C, Iwasaki K. Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica 2006; 36:219-33.
Emoto C, Iwasaki K. Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1’-hydroxylation. Xenobiotica 2007; 37:592-603.
Emoto C, Iwasaki K. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes. Xenobiotica 2007; 37:986-99.
Emoto C, Murase S, Sawada Y, Iwasaki K. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. Drug Metab Pharmacokinet 2005; 20:351-7.
Emoto C, Murase S, Sawada Y, Jones BC, Iwasaki K. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 2003; 18:287-95.
Emoto C, Murayama N, Yamazaki H. Effects of enzyme sources on midazolam 1’-hydroxylation activity catalyzed by recombinant cytochrome P450 3A4 in combination with NADPH-cytochrome P450 reductase. Drug Metab Lett 2008; 2:190-2.
Emoto C, Nishida H, Hirai H, Iwasaki K. CYP3A4 and CYP3A5 catalyse the conversion of the N-methyl-D-aspartate (NMDA) antagonist CJ-036878 to two novel dimers. Xenobiotica 2007; 37:1408-20.
Emoto C, Yamato Y, Sato Y et al. Non-invasive method to detect induction of CYP3A4 in chimeric mice with a humanized liver. Xenobiotica 2008; 38:239-48.
Endo T, Ban M, Hirata K, Yamamoto A, Hara Y, Momose Y. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes. Drug Metab Dispos 2007; 35:476-83.
Endres K, Fahrenholz F. Upregulation of the alpha-secretase ADAM10-risk or reason for hope? FEBS J 2010; 277:1585-96.
Endringer DC, Guimarães KG, Kondratyuk TP, Pezzuto JM, Braga FC. Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara. J Nat Prod 2008; 71:1082-4.
Endrizzi K, Fischer J, Klein K et al. Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction. Anal Biochem 2002; 300:121-31.
Eng C, Crossey PA, Mulligan LM et al. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 1995; 32:934-7.
Eng KT, Berdis AJ. A novel non-natural nucleoside that influences P-glycoprotein activity and mediates drug resistance. Biochemistry 2010; 49:1640-8.
Engblom D, Saha S, Engstrom L et al. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nat Neurosci 2003; 6:1137-8.
Engdal S, Nilsen OG. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res 2009; 23:906-12.
Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 1996; 59:613-23.
Engel T, Kannenberg F, Fobker M et al. Expression of ATP binding cassette-transporter ABCG1 prevents cell death by transporting cytotoxic 7beta-hydroxycholesterol. FEBS Lett 2007; 581:1673-80.
Engelborghs S, Dermaut B, Goeman J et al. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. J Neurol Neurosurg Psychiatry 2003; 74:1148-51.
Engelender S, Sharp A, Colomer V et al. Huntingtin-associated protein 1 (HAP1) interacts with the p150(Glued) subunit of dynactin. Hum Molec Genet 1997; 6:2205-12.
Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43.
Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Cancer Biol Ther 2006; 5:833-9.
Engels FK, Ten Tije AJ, Baker SD et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004; 75:448-54.
Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010; 24:765-70.
English BC, Baum CE, Adelberg DE et al. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag 2010; 6:579-83.
Engman H, Tannergren C, Artursson P, Lennernäs H. Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers. Eur J Pharm Sci 2003; 19:57-65.
Engman HA, Lennernäs H, Taipalensuu J, Otter C, Leidvik B, Artursson P. CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies. J Pharm Sci 2001; 90:1736-51.
Engqvist-Goldstein A, Kessels M, Chopra V, Hayden M, Drubin D. An actin-binding protein of the Sla2/Huntingtin interacting protein 1 family is a novel component of clathrin-coated pits and vesicles. J Clin Biol 1999; 147:1503-18.
Engström K, Vahter M, Mlakar SJ et al. Polymorphisms in arsenic(+III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. Environ Health Perspect 2011; 119:182-8.
Enna S, Bird E, Bennett J et al. Huntington’s chorea: changes in neurotransmitter receptors in the brain. New Eng J Med 1976; 294:1305-9.
Enomoto R, Koshiba C, Suzuki C, Lee E. Wogonin potentiates the antitumor action of etoposide and ameliorates its adverse effects. Cancer Chemother Pharmacol 2011; 67:1063-72.
Enzinger C, Ropele S, Smith S et al. Accelerated evolution of brain atrophy and ‘black holes’ in MS patients with APOE-epsilon-4. Ann Neurol 2004; 55:563-9.
Enzinger C, Ropele S, Strasser-Fuchs S et al. Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon-4 allele. Arch Neurol 2003; 60:65-70.
Eo J, Shin H, Kwon S, Song H, Murphy KM, Lim JH. Complex ovarian defects lead to infertility in Etv5-/- female mice. Mol Hum Reprod 2011; 17:568-76.
Eraly SA. Organic anion transporter 3 inhibitors as potential novel antihypertensives. Pharmacol Res 2008; 58:257-61.
Erdely A, Hulderman T, Salmen-Muniz R et al. Inhalation exposure of gas-metal arc stainless steel welding fume increased atherosclerotic lesions in apolipoprotein E knockout mice. Toxicol Lett 2011; 204:12-6.
Erdely A, Kepka-Lenhart D, Salmen-Muniz R et al. Arginase activities and global arginine bioavailability in wild-type and ApoE-deficient mice: responses to high fat and high cholesterol diets. PLoS One 2010. doi:10. 1371/journal. pone. 0015253.
Erdman AR, Mangravite LM, Urban TJ et al. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol 2006; 290:905-12.
Erdmann J, Hegemann N, Weidemann A et al. Screening the human bradykinin B2 receptor gene in patients with cardiovascular diseases: identification of a functional mutation in the promoter and a new coding variant (T21M). Am J Med Genet 1998; 80:521-5.
Erdös EG, Tan F, Skidgel RA. Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension 2010; 55:214-20.
Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000; 12 Suppl 1:30-44.
Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 1995; 29 Suppl 1:10-8.
Ergen A, Kılıcoglu O, Ozger H, Agachan B, Isbir T. Paraoxonase 1 192 and 55 polymorphisms in osteosarcoma. Mol Biol Rep 2011; 38:4181-4.
Erginel-Unaltuna N, Peoc’h K, Komurcu E, Acuner TT, Issever H, Laplanche JL. Distribution of the M129V polymorphism of the prion protein gene in a Turkish population suggest a high risk for Creutzfeldt-Jakob disease. Europ J Hum Genet 2001; 9:965-8.
Erichsen HC, Engel SA, Eck PK et al. Genetic variation in the sodium-dependent vitamin C transporters, SLC23A1, and SLC23A2 and risk for preterm delivery. Am J Epidemiol 2006; 3:245-54.
Erichsen HC, Peters U, Eck P et al. Genetic variation in sodium-dependent vitamin C transporters SLC23A1 and SLC23A2 and risk of advanced colorectal adenoma. Nutr Cancer 2008; 60:652-9.
Erichsen TJ, Aehlen A, Ehmer U, Kalthoff S, Manns MP, Strassburg CP. Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids. J Hepatol 2010; 52:570-8.
Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27:1488-95.
Erickson R. Chromosomal imprinting and the parent transmission specific variation in expressivity of Huntington disease. Am J Hum Genet 1985; 37:827-9.
Erickson RP, Cao W, Acuña DK et al. Confirmation of using transgenics and knockouts. Mol Reprod Dev 2008; 75:1071-6.
Erickson-Ridout KK, Zhu J, Lazarus P. Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenet Genomics 2011; 21:539-51.
Eriksen JL, Sagi SA, Smith TE et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112:440-9.
Erlich H, Valdes AM, Noble J et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008; 57:1084-92.
Erlotinib: new drug. Non small-cell lung cancer: like gefitinib, no established advantage. Prescrire Int 2006; 15:86-9.
Ernest CS 2nd, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005; 312:583-91.
Ernst E. St John’s wort supplements endanger the success of organ transplantation. Arch Surg 2002; 137:316-9.
Ernst IM, Wagner AE, Lipinski S et al. Cellular uptake, stability, visualization by ‘Naturstoff reagent A’, and multidrug resistance protein 1 gene-regulatory activity of cyanidin in human keratinocytes. Pharmacol Res 2010; 61:253-8.
Ernst T, Hoffmann J, Erben P et al. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2008; 93:1389-93.
Erps LT, Ritter JK, Hersh JH, Blossom D, Martin NC, Owens IS. Identification of two single base substitutions in the UGT1 gene locus which abolish bilirubin uridine diphosphate glucuronosyltransferase activity in vitro. J Clin Invest 1994; 93:564-70.
Errasti-Murugarren E, Pastor-Anglada M. Drug transporter pharmacogenetics in nucleoside-based therapies. Pharmacogenomics 2010; 11:809-41.
Erratico CA, Moffatt SC, Bandiera SM. Comparative oxidative metabolism of BDE-47 and BDE-99 by rat hepatic microsomes. Toxicol Sci 2011; 123:37-47.
Eruvaram NR, Das M. Phenotype of hepatic xenobiotic metabolizing enzymes and CYP450 isoforms of sanguinarine treated rats: effect of P450 inducers on its toxicity. Toxicol Mech Methods 2009; 19:510-7.
Escayg A, de Waard M, Lee DD et al. Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet 2000; 66:1531-9.
Esch FS, Keim PS, Beattie EC et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 1990; 248:1122-4.
Escher G, Vögeli I, Escher R et al. Role of CYP27A1 in progesterone metabolism in vitro and in vivo. Am J Physiol Endocrinol Metab 2009; 297:949-55.
Eseverri J. Projection of new antihistamines. Allergol Immunopathol 2000; 28:143-52.
Eshkoli T, Sheiner E, Ben-Zvi Z, Holcberg G. Drug transport across the placenta. Curr Pharm Biotechnol 2011; 12:707-14.
Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95:9465-70.
Esler WP, Wolfe MS. A portrait of Alzheimer secretases – New features and familiar faces. Science 2001; 293:1449-54.
Espelt MV, Croci DO, Bacigalupo ML et al. Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization and in vivo tumor growth. Hepatology 2011; 53:2097-106.
Estany-Gestal A, Salgado-Barreira A, Sánchez-Diz P, Figueiras A. Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review. Pharmacogenet Genomics 2011; 21:357-64.
Esteban LM, Fong C, Amr D et al. Promoter-, cell-, and ligand-specific transactivation responses of the VDRB1 isoform. Biochem Biophys Res Commun 2005; 334:9-15.
Esterbauer H, Schneitler C, Oberkofler H et al. A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001; 28:178-83.
Esteva FJ, Guo H, Zhang S et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010; 177:1647-56.
Estey T, Cantore M, Weston PA, Carpenter JF, Petrash JM, Vasiliou V. Mechanisms involved in the protection of UV-induced protein inactivation by the corneal crystallin ALDH3A1. J Biol Chem 2007; 282:4382-92.
Esther CR, Marino EM, Howard TE et al. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997; 99:2375-85.
Etheridge AS, Black SR, Patel PR, So J, Mathews JM. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 2007; 73:731-41.
Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 2010; 69:58-66.
Evans AE, Poirier O, Kee F et al. Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. Quart J Med 1994; 87:211-4.
Evans AH, Pancholi S, Farmer I et al. EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy. Br J Cancer 2010; 102:1235-43.
Evans AM. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit 2000; 22:131-6.
Evans D, Bode A, von der Lippe G, Beil FU, Mann WA. Cerebrovascular atherosclerosis in type III hyperlipidemia is modulated by variation in the apolipoprotein A5 gene. Eur J Med Res 2011; 16:79-84.
Evans DA, Harmer D, Downham DY et al. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. J Med Genet 1983; 20:321-9.
Evans DC, O’Connor D, Lake BG, Evers R, Allen C, Hargreaves R. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 2003; 31:861-9.
Evans JP, Kandel S, Ortiz de Montellano PR. Isocyanides inhibit human heme oxygenases at the verdoheme stage. Biochemistry 2009; 8:8920-8.
Evans JP, Xu F, Sirisawad M, Miller R, Naumovski L, de Montellano PR. Motexafin gadolinium-induced cell death correlates with heme oxygenase-1 expression and inhibition of P450 reductase-dependent activities. Mol Pharmacol 2007; 71:193-200.
Evans MV, Caldwell JC. Evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling for in vivo inhalation gas uptake data exposure in female B6C3F1 mice. Toxicol Appl Pharmacol 2010; 244:280-90.
Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin JS. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 1993; 91:2150-4.
Evers DL, Wang X, Huong SM, Andreoni KA, Huang ES. Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778. Antiviral Res 2005; 65:1-12.
Evers R, Kool M, van Deemter L et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 1998; 101:1310-9.
Evert B, Griese EU, Eichelbaum M. Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics 1994; 4:271-4.
Ewald AH, Maurer HH. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6. Toxicol Lett 2008; 183:52-7.
Ewesuedo RB, Dolan ME. Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. Cancer Chemother Pharmacol 2000; 46:150-5.
Ewing MM, de Vries MR, Nordzell M et al. Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler Thromb Vasc Biol 2011; 31:95-101.
Exton MS, Artz M, Siffert W, Schedlowski M. G protein beta3 subunit 825T allele is associated with depression in young, healthy subjects. Neuroreport 2003; 14:531-3.
